Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, inhaled Anticalins to treat respiratory diseases, such as uncontrolled asthma, and a half-life-optimized Anticalin to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Pieris has established a diverse pipeline of Anticalin therapeutics for different indications and has strong R&D collaborations with AstraZeneca, Servier, Roche, Daiichi Sankyo, the Sanofi Group and others.
Anticalin proteins are engineered versions of lipocalins, human proteins that naturally bind, store and transport a wide spectrum of molecules. Our libraries of more than 100 billion different Anticalin proteins have repeatedly delivered drug candidates binding to a very broad spectrum of therapeutic targets.
In 2017, Pieris signed a series of transformative deals for the Company, including a strategic alliance in immuno-oncology with Servier and in respiratory diseases with AstraZeneca.
Pieris is listed on the NASDAQ and trades under the ticker symbol PIRS.